Short Interest in Artivion, Inc. (NYSE:AORT) Drops By 15.4%

Artivion, Inc. (NYSE:AORT) was the target of a significant decline in short interest during the month of February. As of February 13th, there was short interest totaling 1,386,551 shares, a decline of 15.4% from the January 29th total of 1,638,404 shares. Based on an average daily trading volume, of 489,962 shares, the days-to-cover ratio is presently 2.8 days. Currently, 3.2% of the shares of the stock are sold short. Currently, 3.2% of the shares of the stock are sold short. Based on an average daily trading volume, of 489,962 shares, the days-to-cover ratio is presently 2.8 days.

Analysts Set New Price Targets

Several research analysts have issued reports on AORT shares. Oppenheimer reaffirmed an “outperform” rating and set a $50.00 price objective on shares of Artivion in a report on Friday, November 7th. Wall Street Zen lowered Artivion from a “buy” rating to a “hold” rating in a research note on Saturday, February 14th. Needham & Company LLC reiterated a “buy” rating and issued a $58.00 price objective on shares of Artivion in a research report on Monday, February 2nd. Citizens Jmp boosted their price objective on Artivion from $47.00 to $53.00 and gave the stock a “market outperform” rating in a report on Friday, November 7th. Finally, Weiss Ratings raised shares of Artivion from a “sell (d)” rating to a “hold (c-)” rating in a research note on Friday, February 20th. Six research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $50.47.

Artivion Trading Down 1.6%

NYSE:AORT opened at $37.87 on Friday. The company has a current ratio of 3.53, a quick ratio of 2.62 and a debt-to-equity ratio of 0.49. Artivion has a 1-year low of $21.97 and a 1-year high of $48.25. The firm has a market capitalization of $1.81 billion, a price-to-earnings ratio of 189.36 and a beta of 1.60. The business’s 50-day moving average price is $41.24 and its two-hundred day moving average price is $42.88.

Artivion (NYSE:AORT) last announced its quarterly earnings results on Thursday, February 12th. The company reported $0.17 EPS for the quarter, beating analysts’ consensus estimates of $0.14 by $0.03. The company had revenue of $118.30 million during the quarter, compared to analysts’ expectations of $116.42 million. Artivion had a return on equity of 7.43% and a net margin of 2.21%.The firm’s revenue for the quarter was up 19.2% on a year-over-year basis. On average, equities analysts expect that Artivion will post 0.37 earnings per share for the current year.

Insider Buying and Selling at Artivion

In other Artivion news, insider John E. Davis sold 4,573 shares of the business’s stock in a transaction dated Tuesday, March 3rd. The shares were sold at an average price of $37.78, for a total value of $172,767.94. Following the completion of the transaction, the insider directly owned 230,794 shares of the company’s stock, valued at approximately $8,719,397.32. The trade was a 1.94% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Lance A. Berry sold 6,316 shares of the stock in a transaction that occurred on Tuesday, March 3rd. The shares were sold at an average price of $37.78, for a total transaction of $238,618.48. Following the sale, the executive vice president directly owned 210,827 shares in the company, valued at $7,965,044.06. This trade represents a 2.91% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 137,615 shares of company stock worth $5,180,246 over the last quarter. Corporate insiders own 7.60% of the company’s stock.

Hedge Funds Weigh In On Artivion

A number of hedge funds and other institutional investors have recently made changes to their positions in AORT. Summit Partners Public Asset Management LLC bought a new stake in shares of Artivion in the 4th quarter valued at $39,401,000. Invesco Ltd. lifted its holdings in Artivion by 211.9% during the fourth quarter. Invesco Ltd. now owns 1,101,239 shares of the company’s stock worth $50,228,000 after acquiring an additional 748,119 shares in the last quarter. Champlain Investment Partners LLC acquired a new position in Artivion in the third quarter valued at about $17,912,000. Goldman Sachs Group Inc. increased its holdings in shares of Artivion by 144.4% in the fourth quarter. Goldman Sachs Group Inc. now owns 537,375 shares of the company’s stock worth $24,510,000 after acquiring an additional 317,518 shares in the last quarter. Finally, Two Sigma Investments LP raised its position in shares of Artivion by 235.5% during the third quarter. Two Sigma Investments LP now owns 446,535 shares of the company’s stock worth $18,906,000 after purchasing an additional 313,446 shares during the period. 86.37% of the stock is owned by institutional investors.

Key Artivion News

Here are the key news stories impacting Artivion this week:

• Positive Sentiment: Quarterly results beat expectations (EPS and revenue) and showed ~19% YoY revenue growth, supporting the growth narrative and analyst conviction. MarketBeat – Artivion Earnings Summary
• Positive Sentiment: Management will present at the Oppenheimer Healthcare MedTech & Services Conference — a near‑term event where guidance, commercialization updates or product milestones could be disclosed and re‑ignite buy‑side interest. Artivion to Participate in Oppenheimer Conference
• Positive Sentiment: Large institutional buying (notably Invesco’s sizable Q4 add and other funds increasing exposure) can provide steadier bid support and signals professional investor confidence. MarketBeat – Institutional Activity
• Neutral Sentiment: Analyst coverage remains constructive (consensus “Moderate Buy” with elevated price targets), which helps sentiment but may already be priced in. MarketBeat – Analyst Ratings
• Neutral Sentiment: Industry pieces highlight portfolio expansion and relative EPS performance on the NYSE Composite — useful narrative fuel but not an immediate catalyst. Kalkine – Portfolio Expansion Article
• Negative Sentiment: Clustered insider selling March 2–4: CEO James Mackin sold 17,887 shares (~$676k), EVP Lance Berry sold ~6,316 shares (~$238k), other senior execs (SVPs, CAO Amy Horton and others) sold multiple tranches. Markets often interpret concentrated senior‑level sales as a negative near‑term signal despite insiders retaining large stakes. See filings and coverage. SEC Form 4 – Mackin Benzinga – CCO Trade Benzinga – Lance Berry Sale

Artivion Company Profile

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.